###### Strengths and limitations of this study

-   This is the first multi-site harm reduction focused cohort of practices in people who inject drugs (PWID) conducted in France.

-   The study's findings will help to assess the impact of drug consumption rooms and other harm reduction services on HIV and hepatitis C virus risk practices in PWID.

-   The findings will also assess the needs of PWID in France by providing a greater understanding of their social conditions, access to prevention and treatment services.

-   Non-French-speaking PWID are excluded from the cohort so their specific needs are not assessed; they may represent up to 20% of people who attend harm reduction facilities in some sites.

Introduction {#s1}
============

Rationale {#s1a}
---------

In France, as elsewhere, people who inject drugs (PWID) faced a dramatic HIV epidemic in the 1990s. In response, the French government's harm reduction policy, which first developed programmes for access to sterile injection material in 1987, extended access in 1994 to include syringe vending machines and the sale of ready-to-use injection kits (Steribox) in community pharmacies,[@R1] as well as new state-funded needle exchange programmes (NEP).[@R2] These public health initiatives were concomitant with opiate maintenance treatment (OMT) programmes with methadone (available since 1994) and buprenorphine (available since 1995)[@R3] and HAART for HIV-infected individuals.[@R5] HIV prevalence in PWID dramatically decreased from 40% to 20% in 14 years from 1988 to 2002,[@R2] with a prevalence in 2011 of 10%.[@R7] An estimated 77% to 85% of opioid-dependent individuals in France are currently treated with OMT.[@R7]

Despite this progress, and just as in many countries where OMT and NEP are available,[@R8] the impact of this harm reduction policy on the hepatitis C virus (HCV) epidemic in France has not been as great as that for HIV.[@R2] This is because this policy was adopted when HCV prevalence was already too high to be rapidly controlled. In 2011, HCV infection prevalence in the country was 64% among many PWID.[@R7] HCV incidence was also very high, between 11% and 22%,[@R13] compared with neighbouring countries such as the Netherlands.[@R14] The delay in implementing an efficient harm reduction policy may explain the persistent high national prevalence of HCV in PWID today.[@R15] Besides HCV and HIV infections, numerous other physical problems can result from injecting drug use, including soft tissue infections,[@R16] cardiovascular and pulmonary complications,[@R18] and bacterial and fungal infections.[@R19] In addition, research on existing drug consumption rooms (DCR) showed that they improve access to primary healthcare and improve safer injection conditions.[@R20] By attracting the most marginalised PWID,[@R21] they also reduce the level of public injection and so the number of used syringes has dropped in public spaces.[@R22] Finally, it has also been shown that DCR are effective in reducing fatal overdoses.[@R23]

Despite the French health authorities' reluctance to open DCR for many years, mostly because of the country's persistent repressive policy towards drug use and general negative public opinion,[@R24] their success in other countries encouraged the French government to reconsider DCR as a possible additional harm reduction (HR) tool. Two DCR, in Paris and Strasbourg, were opened in 2016 as part of a 6 year experiment granted on the condition that the health and social impact of the facilities would be rigorously evaluated. These two DCR accept all PWID 18 years or older and provide the following services: the possibility to administer drugs by injection (or inhalation in some cases, only for PWID), access to social, medical and psychiatric consultations, the provision of sterile equipment, the collection and disposal of used injection equipment, primary care, harm reduction counselling and HCV, hepatitis B virus (HBV) and HIV testing. In this perspective, the COSINUS cohort (COhort to identify Structural and INdividual factors associated with drug Use) was set up in 2016 to prospectively evaluate the impact of DCR on the reduction of risk-taking behaviours in PWID.

The main objective of this article is to describe the design of the COSINUS cohort study and outline which issues it will explore to evaluate the impact of the DCR on PWID outcomes.

Research objectives and hypothesis {#s1b}
----------------------------------

The main objective of COSINUS is to evaluate the impact of regular DCR use on HIV and HCV risk practices. The hypothesis is that PWID with regular access to DCR have fewer practices at risk of HCV and HIV transmission than PWID with no access. It will also investigate the impact of regular DCR use on access to care. Furthermore, data from COSINUS will be used to study the impact of other individual (eg, age, gender, ethnicity, housing) and structural (eg, exposure to social services, harm reduction services including education about safer injection)[@R25] factors on several outcomes (other risk practices, criminality, current drug use, negative life events, etc.). More specifically, it will help provide a greater understanding of the combined effect of different harm reduction services on PWID health and risk practices.

Methods and analysis {#s2}
====================

Study design {#s2a}
------------

This prospective, multi-center cohort study, which started in June 2016, will enrol a total of 680 PWID by October 2017 in four different French cities with different geographical and health characteristics (Bordeaux, Marseilles, Paris and Strasbourg). The study design and data collection tools were partly inspired by an evaluation of the Vancouver Downtown Eastside DCR (Insite)[@R26] and the Vancouver Injection Drug User Study.[@R27] Individual follow-up will last 12 months. PWID in the DCR in Paris and Strasbourg constitute the 'treatment' group (hereafter 'DCR-exposed'), while PWID already enrolled in harm reduction programmes constitute the 'control' group (hereafter 'DCR-unexposed'). These four cities were chosen because they were all candidates for the opening of DCR when the law permitting experimentation with DCR passed (Public Health Law from January 2016). Data collection consists of face-to-face interviews (each lasting approximately 20--35 min) administered by a trained interviewer at baseline, 3 months, 6 months and 12 months. Data collection is coordinated by the logistics department of methodology and management (CMG) of ORS PACA -- INSERM-IRD UMR1252 (SESSTIM) in Marseilles, under the supervision of the cohort's four PIs (Marc Auriacombe for Bordeaux, Perrine Roux for Marseilles, Marie Jauffret-Roustide for Paris and Laurence Lalanne-Tongio for Strasbourg), and is managed by each site investigator. Participants are compensated for their time with €10 worth of service vouchers after each of the four interviews.

Participants {#s2b}
------------

Subjects were eligible if they self-reported injecting illicit drugs except cannabis (heroin, cocaine/crack, amphetamines, ecstasy) and/or prescription drugs (methylphenidate, buprenorphine, benzodiazepines, morphine sulfate, oxycodone, methadone) at least once during the previous month. Participants must be over 18 years old and French-speaking. There are no specific exclusion criteria, except if the PWID does not fulfil the inclusion criteria, for example non-French-speaking PWID are excluded. Participants must also provide informed consent to participate in the study. They were recruited mainly in the DCR (in the cities where there is one) and in other harm reduction facilities that currently outreach to PWID likely to attend a DCR if available in each city. This mix of recruitment sites was chosen in order to be able to compare PWID between cities. To avoid duplicate enrollment, the month, year and place of birth are recorded for each participant.

Measures {#s2c}
--------

The evaluation of DCR is based on the following main outcome: the proportion of participants reporting at least one injection-related HIV-HCV risk practice (sharing of syringes/needles, sharing of other injecting paraphernalia (filter, swab, water, cup, etc.)) in the previous month.

The other variables that will be collected are: socio-demographic characteristics (gender, age, housing, employment, living in a couple, ethnicity, parenthood, social allowances, country of birth); history of drug use (age at first drug use, first injection and related context); current drug and alcohol use (type, frequency, quantity of drugs used, context of drug use, use disorder diagnostic criteria, craving); overdoses and suicide risk; drug use-related HIV-HCV risk practices (injecting, snorting, smoking, sharing and reusing injecting equipment); addiction treatments; DCR attendance; health conditions and access to care and prevention (type and frequency of care, satisfaction with care, HIV, HCV and HBV screening and self-reported HIV and HCV status, education in injection, other HR services); criminality (illegal activities and experience of prison); negative life events (violence, sexual assault, loss of a relative, etc.); psycho-social assessment (anxiety, ADHD, PTSD, etc.); injection initiation (experience and context); cognitive assessments (GONOGO, mnesic test); sexual health (sexual risk practices, contraception); discrimination and life course (parents, childhood).

This interview questionnaire includes the full version or some items from several already validated questionnaires as follows: (1) the Blood-Borne Virus Transmission Risk Assessment [@R28] to evaluate the risk practice; (2) a section of the Addiction Severity Index, which is a multi-dimensional questionnaire that measures drug use based on participants' self-report[@R29]; (3) the Alcohol Use Disorders Identiﬁcation Test (AUDIT-C) questionnaire to measure alcohol consumption[@R31]; (4) a set of questions from the PRIMER study to examine injection initiation[@R32]; (5) three validated questionnaires to measure psychiatric outcomes: the 25-item Wender Utah Rating Scale for attention-deficit/hyperactivity disorder screening,[@R33] the Beck Anxiety Inventory to measure anxiety[@R34] and the Post-traumatic stress event questionnaire[@R35]; (6) finally, two questionnaires measure participants' cognitive ability: the go-no go task[@R37] and the mnesic test.[@R38]

[Table 1](#T1){ref-type="table"} displays the schedule for each assessment.

###### 

Summary of data collection at each follow-up visit

                                                    M0   M3   M6   M12
  ------------------------------------------------- ---- ---- ---- -----
  Socio-demographic characteristics                 x    x    x    x
  Socio-economic characteristics                    x    x    x    x
  History of substance use                          x              
  Current drug use                                  x    x    x    x
  Alcohol and tobacco use                           x    x    x    x
  Overdoses and suicidal risk                       x         x    x
  Drug use-related HIV-HCV risk practices           x    x    x    x
  Addiction treatment                               x    x    x    x
  Health conditions and access to care              x         x    x
  Screening for HIV and HCV                         x         x    x
  Criminality                                       x    x    x    x
  Prison experience                                 x         x    x
  Negative life events                              x              x
  Initiation injection                              x         x    x
  HR services user satisfaction                     x         x    x
  Sexual health                                          x         
  Other practices at risk of dermal contamination        x         
  DCR attendance and other services                 x    x    x    x
  Life course                                            x         
  Attention Deficit Hyperactivity Disorder               x         
  Anxiety: Beck anxiety inventory                             x    
  Post-traumatic stress disorder                              x    
  Discrimination                                         x         
  GONOGO Task                                            x         x
  Mnemonic Test                                          x         x

DCR, drug consumption rooms; HCV, hepatitis C virus; HR, harm reduction.

Sample size {#s2d}
-----------

The main outcome is the comparison of the percentage of PWID reporting at least one injection-related HIV-HCV risk practice during the previous month between the DCR-exposed and DCR-unexposed groups. The sample size needed was calculated according to this main outcome. Many studies from different countries with DCR have shown that between 30%[@R39] and 60%[@R41] of users regularly attend them (at least once a week). In the French context, the proportion of PWID reporting at least one injection-related HIV-HCV risk practice varies according to the context and the characteristics of PWID recruited in different studies, from 25%[@R25] to 50%.[@R42] We hypothesise 33% of regular (ie, at least once a week) DCR attending participants will report at least one of these events. Supposing that one-third of participants will regularly attend DCR, with an alpha=5% and a power of 80%, we need a total of 131 participants in each group. Given an expected attrition rate of 40% after 12 months of follow-up,[@R43] the sample size is therefore 680 (Paris=250, Marseilles=200, Bordeaux=150, Strasbourg=80).

Statistical methods {#s2e}
-------------------

COSINUS was developed to show the impact of DCR on HIV-HCV risk practices. Longitudinal data analysis will use a mixed logistic model to assess the impact of individual factors (socio-demographic, behavioural and cognitive data) and structural factors, including DCR attendance and exposure to other HR services (access to OMT, social services, education to safer injection, etc.), on the main outcome (reporting at least one injection-related HIV-HCV risk practice during the previous month). Data analysis will be carried out with logistic regression models for qualitative data in two ways: multinomial regression for qualitative data of more than two terms or linear regression for continuous data. In addition, to study the impact of the combined effect of different services (DCR, education about safe injection, other HR services) on the main outcome, we will use mixed-model regression analysis by adjusting for these different structural factors and other covariates. A Cox model-based approach (or duration models) will be used to study the impact of DCR attendance (or other HR services) for a certain event at a certain time (transition from injection to another mode of use, access to care). To take into account bias due to missing data and loss to follow-up, we will perform sensitivity analyses using the Heckman model, which adjusts for this potential source of statistical bias.[@R44] Analyses will be performed using several statistical software packages (SPSS V.12.0, Intercooled Stata V.10.0 and SAS; statistical V.10.0).

Patient and public involvement {#s2f}
------------------------------

Although participants did not directly contribute to the design of the study or to the development of the research questions, their needs and preferences were considered throughout the process. Feedback to the participants regarding scientific results, will be organised on each study site.

Discussion {#s3}
==========

The COSINUS cohort study is the first in France designed to assess the impact of DCR on HIV-HCV risk practices. It is important to note that DCR in France are seen as an additional tool to existing NEP and OMT programmes, as well as the recently education programme for safer injecting practices.[@R25]

To date, most of the data published on the effects of DCR are from the Vancouver INSITE research team,[@R45] whose work greatly contributed to the preliminary design of our cohort study. However, the French and Vancouver contexts are very different in terms of substances available on the black market, access to OMT, sharing practices, sero-prevalence of HIV and HCV, and harm reduction policy. In France, an estimated 180 000 drug users are currently on OMT,[@R46] corresponding to an estimated coverage of 80% in urban areas.[@R7] Two-thirds of individuals receiving OMT are treated with buprenorphine. This figure contrasts with other high-level income countries, where methadone is more accessible.[@R47] This high coverage of OMT may have played a role in decreasing long-term HCV prevalence over recent years.[@R2] The decrease in prevalence of HCV has been slower than that seen for HIV. This reflects the situation in other European countries such as the Netherlands and Switzerland.[@R48] Overall, despite high coverage of prevention and treatment services, HCV prevalence data suggest that PWID, including those receiving OMT,[@R49] still have a high risk of transmitting HCV.[@R15] DCR can therefore be an addition to existing HCV prevention tools by engaging difficult-to-rich PWID in OMT and safer injection practices.

Although there are differences between the French and Vancouver contexts in terms of black market substance abuse (see above), and despite some heterogeneity across and within the four different metropolitan areas where our study is being conducted,[@R7] similarities between the two contexts exist, specifically regarding reduced access to sterile syringes, low socio-economic levels and a high proportion of PWID injecting in public spaces.[@R7] COSINUS will help us understand the dynamic of HIV-HCV risk practices at a national level, both in already existing DCR and in sites providing other HR services. In France, incidence of fatal overdoses among PWID is low, making it difficult to reduce it significantly over a 12 month period. This could be related to the national harm reduction policy implemented in the 1990s including access to OMT[@R6] and a high level of OMT coverage.[@R7]

Many prospective studies have tested, evaluated and validated DCR worldwide and have shown several benefits for public health.[@R20] Although public opinion on DCR is mixed and has seen shifting attitudes over time,[@R24] DCR acceptance by drug users and the drug-using community has been positive to date.[@R52] Any evaluation of DCR needs to take into account the social environment where DCR are implemented, especially social acceptability by the neighbourhood.[@R56] DCR facilitate access to needles and provide safer places for users at high risk both to themselves and to their environment.[@R41] They provide hygienic and safe conditions for intravenous users and staff. They reduce morbidity and mortality associated with overdoses and with HIV and HCV infections, which is not only beneficial to PWID but increases healthcare cost-effectiveness.[@R59] They promote access to opioid dependence treatment[@R60] and to prevention interventions related to drug injecting practices.[@R61] However, few existing DCR provide education programmes for safer injection[@R63] or have a space to inhale drugs. Moreover, data about the combined effect of DCR with other HR services are sparse. The Canadian experience has shown the importance of the evaluation process of such a controversial HR tool.[@R64] More specifically, evidence-based findings from an evaluation process of the DCR 'Insite' helped to advocate against its closure, which was threatened by the federal government.[@R66] The COSINUS cohort study will not only study the impact of regularly attendance in DCR on HIV-HCV risk practices in PWID in France, but will also assess the combined effect of DCR together with other HR services (eg, education about safer injection, access to OMT, social activities) on these practices.

Some limitations have to be acknowledged. First, all the data collected were self-reported. Although the use of self-reports may be subject to social desirability bias, studies have shown their reliability in drug-using populations.[@R67] To control any such bias, we used trained interviewers independent of the participating harm reduction facilities. In terms of the diversity of our sample, all the PWID were recruited through easily accessible harm reduction facilities that conduct outreach actions, and which constitute the main contact that the PWID population has with the healthcare system. Another limitation is that, due to cost limitations of our study, we enrolled only French-speaking participants. Further studies are planned to better investigate the impact of DCRs in all the population of PWID including non-French-speaking PWID that represent around 20% of people who attend DCRs.[@R69]

In addition to evaluating DCR and other HR services, this cohort will be used for a more global assessment of the needs of the PWID population in terms of access to treatment for addictive disorders. It will also examine the reasons for not seeking treatment, while identifying users who may benefit from it. It will help to provide a greater understanding of users' social conditions, practices, their access to prevention and treatment services and of the role of incarceration and violence in this population often excluded from the healthcare system.

Ethics and dissemination {#s4}
========================

All procedures performed were in accordance with the 1964 Helsinki declaration and its later amendments. All participants in the survey gave their informed consent.

The results from this cohort will enable health authorities shape health and harm reduction policies according to PWID needs, as well as improve and create novel harm reduction and therapeutic interventions. All relevant results will be published in peer-reviewed international scientific journals and presented at conferences, nationally and internationally.
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